[A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer].
[A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer].
复制标题
胃癌术后辅助免疫化疗的多机构研究[J].
DOI：
--
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
N. Ogawa
中科院分区：
文献类型：
--
作者：
T. Nakajima;K. Inokuchi;T. Hattori;K. Inoue;T. Taguchi;T. Kondo;O. Abe;K. Kikuchi;T. Tanabe;N. Ogawa
本文分析了412个单位3,630例胃癌患者随机分配的6种治疗方案，研究了PSK和Futraful每日给药的效果，以及PSK和/或Picibanil（OK 5 KE）联合MMC和FT的辅助作用。根据3年生存率和免疫指标对免疫化疗进行评价。最积极的结果是，在相对早期的患者中，联合治疗（FT + PSK）优于单次给药（FT）（30%，差异），PSK，MMC和FT联合治疗（10%），PSK，OK，MMC和FT（22%）优于单次化疗（22%）。血清α-2球蛋白水平，表明免疫抑制，在PSK管理的情况下较低。总体结果表明PSK和/或OK联合MMC和FT可有效延长术后患者的生命。
An analysis of 3,630 gastric cancer cases from 412 institutions who were treated with 6 randomly-assigned protocols was carried out to study the effect of daily PSK and Futraful administration and the adjuvant effect of PSK and/or Picibanil (OK 5 KE) combined with MMC and FT. Evaluation of immunochemotherapy was made on the basis of three-year survival rates and immunoparameters. The most positive results were found in survival rates favoring the combined therapy (FT + PSK) over single administration (FT) to relatively early-stage patients (30%, difference), PSK, MMC and FT combination (10%), and PSK, OK, MMC and FT (22%), over single chemotherapy alone. Serum alpha-2 globulin levels, indicative of immunosuppression, were lower in PSK-administered cases. The overall findings indicated that PSK and/or OK with MMC and FT are effective in prolonging the lives of post-operative patients.